AbbVie's elagolix has shown promise in a phase 2 trial in women with uterine fibroids, a second indication for the pipeline drug, which could become a major earner for the company.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
